Cocrystal Pharma, Inc.
COCP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001412486
In the last 90 days, Cocrystal Pharma, Inc. insiders filed 2 open-market purchases and 0 sales; 27 institutions reported holding it in 13F filings for Q2 2026, worth $1.17M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Cocrystal Pharma, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 22 | 28 | +6 |
| Shares | 665.0K | 770.6K | +105.5K (+15.9%) |
| Value | $831.3K | $754.3K | −$76.9K (−9.3%) |
New holders (7)
Institutions that held Cocrystal Pharma, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| T3 Companies, LLC | 52,300 | $51.2K | 0.07% |
| DRW Securities, LLC | 33,593 | $32.9K | 0.00% |
| XTX Topco Ltd | 15,141 | $14.8K | 0.00% |
| Two Sigma Securities, LLC | 12,752 | $12.5K | 0.00% |
| Fortitude Family Office, LLC | 3,219 | $3.15K | 0.00% |
| Root Financial Partners, LLC | 7 | $7 | 0.00% |
| Motiv8 Investments LLC | 42 | $0 | 0.00% |
Sold out (1)
Institutions that held Cocrystal Pharma, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Barclays PLC | 16 | $20 |